In the 20–30% of patients with CBF or NPM1-mutated AML who relapse, chemosensitivity is usually maintained and a second CR can be obtained in 50 to 80% of patients after salvage therapy, with consolidative allogeneic HCT being associated with better overall survival (OS) [4–8]. Here, NPM1 is linked to acute myeloid leukemia.